Idorsia Expands Latin American Reach with EMS Licensing Deal for Insomnia Drug
Event summary
- Idorsia has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ (daridorexant) in Latin America.
- A regulatory filing for QUVIVIQ with ANVISA in Brazil was submitted in 2025.
- Idorsia will receive USD 20 million in milestone payments and royalties on net sales in Brazil and Mexico.
- EMS, Brazil’s largest privately-owned pharmaceutical company, will handle registration and commercialization.
The big picture
Idorsia’s deal with EMS represents a strategic shift towards leveraging established regional players to accelerate global expansion of QUVIVIQ. The partnership addresses the significant unmet need for effective insomnia treatments in Latin America, a market often underserved by existing therapies due to side effects. This move underscores a broader trend of pharmaceutical companies utilizing localized partnerships to navigate complex regulatory landscapes and distribution networks in emerging markets.
What we're watching
- Regulatory Approval
- The speed of ANVISA’s approval process will be a key indicator of market entry timelines and potential revenue generation for QUVIVIQ in Brazil.
- Market Penetration
- EMS’s commercial execution and ability to displace existing insomnia treatments will determine the ultimate success of the partnership in Latin America.
- Sub-licensing
- The extent to which EMS secures sub-licensees in other Latin American countries will influence Idorsia’s overall royalty income and regional market coverage.
Related topics